Characteristics of the patients with heart disease in a health area of A Coruña province. Barbanza 2000 study;Características de los pacientes con cardiopatías en un área sanitara de la provincia de A Coruña. Estudio Barbanza 2000

Revista Clinica Espanola

Volumn 203, Issue 12, 2003, Pages 570-576

  Gonzalez Juanatey J R ^a   Besada Gesto, J R ^b   de Blas Abad, P ^b   Dominguez Lopez J ^b   Feijoo Guarros N ^b   Fernandez Villaverde J M ^b   Gomez Vazquez J L ^b   Gutierrez Fernandez M G ^b   Juiz Crespo, A ^b   Lago Fernandez M J ^b   Lado Llerena, A L ^b   Lado Lopez M ^b   Lage Rodriguez A ^b   Maestro Saavedra, F J ^b   Muniz Fontaina S M ^b   Nores Lorenzo, A ^b   Pastor Benavent, M C ^b   Perez Llamas M ^b   Rodriguez Moldes E ^b   Sanchez Loureiro M ^b   Santos Rodriguez J A ^b   Torres Colomer, J ^b   Toucedo Lorenzp, J M ^b   Turrado Turrado, V ^b   Vaamonde Mosquera, L ^b   more..

^a Instituto de Salud Carlos III   (Spain)

^b NONE

Author keywords

Epidemiological; Heart disease; Risk factors; Treatment

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOLYTIC AGENT; HYDROCHLOROTHIAZIDE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; COOPERATION; DEMOGRAPHY; DIABETES MELLITUS; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; INTERPERSONAL COMMUNICATION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; PATIENT CARE; PRIMARY MEDICAL CARE; PROSPECTIVE STUDY; QUESTIONNAIRE; REGISTRATION; SPAIN; SYSTOLIC BLOOD PRESSURE;

EID: 9144260554     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2565(03)71361-7     Document Type: Article

References (31)

1. Villar F, Banegas JR, Rodríguez-Artalejo F, Rey J. Mortalidad cardiovascular en España y sus Comunidades Autónomas (1975-1992). Med Clin (Barc) 1998;110:321-7.
2. Sociedad Española de Cardiologia. Estudio de los recursos, necesidades y organización para la atención al paciente cardiológico. Madrid: Sociedad Española de Cardiologia; 1999.
3. Mckee PA, Castelli WP, McNamara PM, Kannel WB. The natural history for congestive heart failure, the Framingham Study. N Engl J Med 1971; 285:1441.
4. Van den Hoogen PCW, Feskens EJM, Nagelkerke NJD, Menotti A, Nissinen A, Kromhout D, et al. The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. N Engl J Med 2000;342:1-8.
5. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D. Is pulse pressure useful in predicting risk of coronary heart disease? The Framingham Heart Study. Circulation 1999;354-60.
6. MacMahon S. Blood pressure and risk of cardiovascular disease. N Engl J Med 2000;342:50-1.
7. Flack JM, Neaton J, Grimm R, Shih J, Cutler J, Ensrud K, et al for the Multiple Risk Factor Intervention Trial Research Group. Blood pressure and mortality among men with prior myocardial infarction. Circulation 1995;92:2437-45.
8. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2,012 participants in the SPAF I-III clinical trials. Stroke 1999; 30:1223-9.
9. Banegas JR, Rodríguez-Artalejo F, de la Cruz JJ, Andrés B, del Rey J. Mortalidad relacionada con la hipertensicón y la presión arterial en España. Med Clin (Barc) 1999;112:489-94.
10. Sans S, Paluzie G, Balaña L, Puig T, Balaguer-Vintró I. Tendencias de la prevalencia, conocimiento, tratamiento y control de la hipertensión arterial entre 1986 y 1996: estudio MONICA-Cataluña. Med Clin (Barc) 2001; 117:246-53.
11. González-Juanatey JR, Alegría E, Lozano JV, Llisterri JL, Garâ-Acuña JM, González-Maqueda I. Impacto de la hipertensión en las cardiopatías en España. Estudio CARDIOTENS 1999. Rev Esp Cardiol 2001;54:139-49.
12. The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.
13. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17:151-83.
14. Lombera F, Barrios V, Soria F, Placer L, Cruz JM, Tomás L, et al. Guías de práctica clínica de la Sociedad Española de Cardiología en hipertensión arterial. Rev Esp Cardiol 2000;53:66-90.
15. Antoñanzas F, Antón F, Juárez CA, Echevarría L. Coste de la insuficiencia cardíaca crónica en España. An Med Interna, 1997;14:9-14.
16. Brotóns C, Moral I, Ribera A, Pérez G, Cascant P, Bustins M, et al. Tendencias de morbimortalidad por insuficiencia, cardíaca en Cataluña. Rev Esp Cardiol 1998;51:972-6.
17. Rodríguez-Artalejo F, Guallar P, Banegas JR, del Rey J. Trends in hospitalisation and mortality for heart failure in Spain 1980-1993. Eur Heart J 1997;18:1771-9.
18. Conthe P, Pacho E. El tratamiento de la insuficiencia cardíaca. Rev Clin Esp 2000;200:551-62.
19. Anguita M, Vallés F. ¿Quién debe tratar la insuficiencia cardíaca? Rev Esp Cardiol 2001;54:815-8.
20. Conthe P, Vilardell M, en nombre de la Junta Directiva de la Sociedad Española de Medicina Interna. Medicina Interna y enfermedades prevalentes. El caso de la insuficiencia cardíaca. Rev Clin Esp 2002;202:63-5.
21. Estudio SEMI-IC. La insuficiencia cardíaca en los servicios de Medicina Interna. Med Clin (Barc) 2002; 118:605- 10.
22. Cosín J, Hernándiz A. Ensayos clínicos en insuficiencia cardíaca. Rev Esp Cardiol 2001;54(Suppl 1):22-31.
23. Cibis II-Investigators and committees. The Cardiac Insufficiency Bisoprolol Study II (Cibis II): a randomised trial. Lancet 1999;353:9-13.
24. MERIT-HF Study Group. Effects of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999;353:2001-7.
25. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55.
26. Vasan RS, Benjamin EJ, Levy D. Prevalence, clinical features and prognosis of diastolic heart failure: an epidemiologic perspective. J Am Coll Cardiol 1995;26:1565-74.
27. EUROASPIRE I and II Group. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357:972-3.
28. Smith SC, Blair SN, Bonow RO, Brass LM, Cerqueira MD, Dracup K, et al. AHA/ACC Guidelines for preventing heart attack and death in patients with atheroesclerotic cardiovascular disease: 2001 Update. Circulation 2001; 104:1577-9.
29. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor ramipril on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-53.
30. De Velasco JA, Cosín J, López-Sendón JL, de Teresa E, de Oya M, Carrasco JL, et al. La prevención secundaria del infarto de miocardio en España. Estudio PREVESE. Rev Esp Cardiol 1997;50:406-15.
31. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (The Cardiovascular Health Study). Am J Cardiol 1994;74:236-41.